BioNTech
phase expansion cohorts ongoing | BioNTech
Company
Deck Type
Sector
Industry
Deck date
March 2022
Slide
21 of 37
Related slides by other companies
Immatics
Investor Presentation
November 2023
phase clinical trial to evaluate targeting | Immatics
Alkermes
Investor Day
March 2021
artistry phase efficacy expansion initiated following determination phase dose week lead in followed by combination of and either or cohorts a to a dose cohorts to dose phase efficacy expansion in solid tumors initiated at combination selected efficacy expansion in select solid tumors where previous responses were observed primary objectives safety and efficacy in combination with subcutaneous recommended phase dose administered once weekly administered once every three weeks secondary objectives include clinical profile and immunogenicity clinical pharmacodynamic effects all parts anti tumor activity phase and objective response rate and dor duration of response phase as fae | Alkermes
Larimar Therapeutics
Investor Presentation
November 2023
phase dose exploration study for and cohorts | Larimar Therapeutics
argenx SE
Results
June 2023
for multifocal motor neuropathy advancing phase study to cohort a | argenx SE
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Investor Day
February 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights